Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli

L-asparaginase is an enzyme used as a chemotherapeutic agent, mainly for treating acute lymphoblastic leukemia. In this study, the gene of L-asparaginase from Zymomonas mobilis was cloned in pET vectors, fused to a histidine tag, and had its codons optimized. The L-asparaginase was expressed extracellularly and intracellularly (cytoplasmically) in Escherichia coli in far larger quantities than obtained from the microorganism of origin, and sufficient for initial cytotoxicity tests on leukemic cells. The in silico analysis of the protein from Z. mobilis indicated the presence of a signal peptide in the sequence, as well as high identity to other sequences of L-asparaginases with antileukemic activity. The protein was expressed in a bioreactor with a complex culture medium, yielding 0.13 IU/mL extracellular L-asparaginase and 3.6 IU/mL intracellular L-asparaginase after 4 h of induction with IPTG. The cytotoxicity results suggest that recombinant L-asparaginase from Z. mobilis expressed extracellularly in E.coli has a cytotoxic and cytostatic effect on leukemic cells.

[1]  O. Hrusak,et al.  Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells , 2004, Leukemia.

[2]  H. Drexler,et al.  Establishment and characterization of human B cell precursor-leukemia cell lines. , 1998, Leukemia research.

[3]  G. Bennett,et al.  Metabolic Engineering of Escherichia coli To Enhance Recombinant Protein Production through Acetate Reduction , 1995, Biotechnology progress.

[4]  M. Greaves,et al.  Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line , 1977, Nature.

[5]  T. Ueno,et al.  Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase , 1997, Leukemia.

[6]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[7]  H. Sather,et al.  Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961 , 2004, Journal of pediatric hematology/oncology.

[8]  Gurnoor Kaur,et al.  L-Asparaginase: A Promising Chemotherapeutic Agent , 2007, Critical reviews in biotechnology.

[9]  T. Alves,et al.  Removal of lactobionic acid by electrodialysis , 2014 .

[10]  E. Hersh,et al.  The inhibition of lymphocyte blastogenesis by L-asparaginase. , 1970, Blood.

[11]  Q. Guo,et al.  Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo. , 2002, Acta pharmacologica Sinica.

[12]  P. Tarli,et al.  Simplified enzymic/colorimetric serum urea nitrogen determination. , 1979, Clinical chemistry.

[13]  Jean-Michel Claverie,et al.  Phylogeny.fr: robust phylogenetic analysis for the non-specialist , 2008, Nucleic Acids Res..

[14]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[15]  A. Papageorgiou,et al.  Structure-function relationships and clinical applications of L-asparaginases. , 2010, Current medicinal chemistry.

[16]  S. S. Kanwar,et al.  Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. , 2007, Critical reviews in oncology/hematology.

[17]  L. Filgueira,et al.  Exogenous glutamine requirement is confined to late events of T cell activation , 1993, Journal of cellular biochemistry.

[18]  J. Ross,et al.  L-asparaginase from Erwinia carotovora. An improved recovery and purification process using affinity chromatography. , 1989, Applied biochemistry and biotechnology.

[19]  M. D. Boer,et al.  Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Heath,et al.  Crystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase I. , 2007, Journal of molecular biology.

[21]  L. Chiarelli,et al.  Helicobacter pyloril-asparaginase: a promising chemotherapeutic agent. , 2008, Biochemical and biophysical research communications.

[22]  T. L. M. Alves,et al.  Adaptive optimal control of fed-batch alcoholic fermentation , 1998, Applied biochemistry and biotechnology.

[23]  M. D. Den Boer,et al.  Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. , 2003, Blood.

[24]  S. Suciu,et al.  Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. , 2002, Blood.

[25]  E. Lima,et al.  A hybrid neural model for the production of sorbitol and gluconic acid using immobilized Zymomonas mobilis cells , 2004 .

[26]  Silvia Franchini,et al.  Cell-Cycle Inhibition by Helicobacter pylori L-Asparaginase , 2010, PloS one.

[27]  Nikolaos E Labrou,et al.  L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization. , 2007, Journal of biotechnology.

[28]  E. Panosyan,et al.  Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations , 2005, Clinical pharmacokinetics.

[29]  M. Schrappe,et al.  Optimizing asparaginase therapy for acute lymphoblastic leukemia , 2013, Current opinion in oncology.

[30]  I. Polikarpov,et al.  Structure, Substrate Complexation and Reaction Mechanism of Bacterial Asparaginases , 2007 .

[31]  R. Bast,et al.  Holland-Frei Cancer Medicine , 2016 .

[32]  S. Martín-Aragón,et al.  Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. , 2007, Anticancer research.

[33]  M. Savio,et al.  Helicobacter pylori releases a factor(s) inhibiting cell cycle progression of human gastric cell lines by affecting cyclin E/cdk2 kinase activity and Rb protein phosphorylation through enhanced p27(KIP1) protein expression. , 2002, Experimental cell research.

[34]  J Dörrie,et al.  Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. , 2001, Cancer research.

[35]  Alberto Orfao,et al.  Overview of clinical flow cytometry data analysis: recent advances and future challenges. , 2013, Trends in biotechnology.

[36]  C. P. Borges,et al.  Sorbitol and gluconic acid production using permeabilized Zymomonas mobilis cells confined by hollow-fiber membranes , 2000, Applied biochemistry and biotechnology.

[37]  K. Mukherjee,et al.  Optimization of extracellular production of recombinant asparaginase in Escherichia coli in shake-flask and bioreactor , 2005, Applied Microbiology and Biotechnology.

[38]  L. Boxer,et al.  A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. , 2005, Cancer research.

[39]  N. Tripathi.  High Yield Production of Heterologous Proteins with Escherichia coli , 2009 .

[40]  T. Alves,et al.  ENZYMATIC CATALYSIS BY PERMEABILIZED CELLS , 1997 .

[41]  A. Periclou,et al.  Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. , 2007, Blood.

[42]  M. Jaskólski,et al.  Preliminary crystallographic studies of Y25F mutant of periplasmic Escherichia coli L-asparaginase. , 2000, Acta biochimica Polonica.

[43]  W. Evans,et al.  Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. , 2005, Blood.

[44]  A. Verma,et al.  Hyperthermophilic asparaginase mutants with enhanced substrate affinity and antineoplastic activity: structural insights on their mechanism of action , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  R. J. Roon,et al.  Reactions of asparaginase II of Saccharomyces cerevisiae. A mechanistic analysis of hydrolysis and hydroxylaminolysis. , 1980, The Journal of biological chemistry.

[46]  V. Avramis.  Asparaginases: biochemical pharmacology and modes of drug resistance. , 2012, Anticancer research.

[47]  Bhairab N. Singh,et al.  Extracellular expression and single step purification of recombinant Escherichia coli L-asparaginase II. , 2004, Protein expression and purification.

[48]  Georgia A. Kotzia,et al.  Cloning, expression and characterisation of Erwinia carotovora L-asparaginase. , 2005, Journal of biotechnology.

[49]  M. D. Den Boer,et al.  Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. , 2003, Blood.

[50]  R. Pieters,et al.  TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. , 2000, Blood.

[51]  Suresh Kumar,et al.  Purification and Characterization of Glutaminase Free Asparaginase from Enterobacter cloacae: In-Vitro Evaluation of Cytotoxic Potential against Human Myeloid Leukemia HL-60 Cells , 2016, PloS one.

[52]  Joseph Shiloach,et al.  Growing E. coli to high cell density--a historical perspective on method development. , 2005, Biotechnology advances.

[53]  K. Sathyaseelan.  High Yield Production of Heterologous Proteins with Escherichia coli , 2009 .